PAI-1 Inhibition in experimental venous thrombosis

Abstract

Background

A novel PAI-1 inhibitor, MDI-2268, has been recently developed. The aim of the study was to evaluate the antithrombotic effects and safety of the MDI-2268 in acute venous thrombosis (VT) in vivo.

Methods

C57BL/6 mice, 10–12 weeks old, weighing 20–25g, were used in electrolytic model of VT (EIM). MDI-2268 1.5 mg/kg (Group 1), MDI-2268 3 mg/kg (Group 2), enoxaparin 7.3 mg/kg (Group 3), and MDI-2268 1.5 mg/kg plus enoxaparin 1.8 mg/kg (Group 4) were compared to the controls (sham surgery). Animals were sacrificed on Day 2. Thrombus weight and tail bleeding time were measured.

Results

TW was 6.9 ± 3.3 (p > .05), 5.5 ± 1.6 (p = .016), 3.8 ± 1.3 (p = .032), and 4.8 ± 2.4 mg (p = .016) for groups 1, 2, 3, and 4, respectively, compared to the controls. Bleeding time was not significantly affected by the MDI-2268.

Conclusions

MDI-2268 is a novel pro-fibrinolytic agent that demonstrates strong antithrombotic properties without prolongation of bleeding time in this experimental model.

Keywords

venous thrombosis plasminogen PAI-1 inhibitor

Get full access to this article

View all access options for this article.

References

Van De Craen

Declerck

Gils

. The biochemistry, physiology and pathological roles of PAI-1 and the requirements for PAI-1 inhibition in vivo. Thromb Res 2012; 130(4): 576–585.

Reinke

Warnock

, et al. Dual-reporter high-throughput screen for small-molecule in vivo inhibitors of plasminogen activator inhibitor type-1 yields a clinical lead candidate. J Biol Chem 2019; 294(5): 1464–1477.

Palmer

Shaydakov

Rainey

, et al. Update on the electrolytic IVC model for pre-clinical studies of venous thrombosis. Res Pract Thromb Haemost 2018; 2(2): 266–273.

Carmeliet

Stassen

Schoonjans

, et al. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J Clin Investig 1993; 92(6): 2756–2760.